Clinical trial of menatetrenone combined with PKP in the treatment of patients with osteoporotic vertebral compression fracture
10.13699/j.cnki.1001-6821.2024.10.004
- VernacularTitle:四烯甲萘醌联合PKP术治疗骨质疏松性椎体压缩骨折患者的临床研究
- Author:
Yan ZHU
1
;
Lei-Yu QIU
;
Xiao ZHOU
Author Information
1. 诸暨市人民医院脊柱外科,浙江诸暨 311800
- Keywords:
menatetrenone capsules;
osteoporotic vertebral compression fracture;
percutaneous kyphoplasty;
bone me-tabolism
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(10):1409-1413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect and safety of menatetrenone combined with percutaneous kyphoplasty(PKP)in the treatment of osteoporotic vertebral compression fracture(OVCF).Methods Patients with OVCF were divided into treatment group and control group by random number table method.The control group was treated with PKP and conventional anti-osteoporosis treatment,and the treatment group was treated with menatetrenone 15 mg,tid,on the basis of control group.The two groups were compared on the changes in T value of bone mineral density,Oswestry disability index(ODI)scores,visual analogue scale(VAS)and bone metabolism indicators[osteocalcin(OC),alkaline phosphatase(ALP),C-telopeptide of type Ⅰ collagen(CTX-Ⅰ)and 25-hydroxyvitamin D(25(OH)D)].The incidence rates of refracture and adverse reactions were recorded.Results There were 40 cases in treatment group and 40 cases in control group.After treatment,T values of bone mineral density of lumbar spine(L2-4)in treatment group and control group were-1.79±0.24 and-2.16±0.28;T values of bone mineral density of femoral neck were-1.44±0.16 and-2.01±0.22;T values of bone mineral density of femoral great trochanter were-1.76±0.18 and-1.97±0.23,all with significant difference(all P＜0.05).Three months after operation,ODI scores in treatment group and control group were 34.12±3.56 and 37.67±3.89;six months after operation,ODI scores were 17.85±1.84 and 26.75±2.78;three months after operation,VAS were 2.61±0.28 and 2.84±0.31;six months after operation,VAS were 0.85±0.11 and 1.23±0.16,all with significant difference(all P＜0.05).After treatment,OC levels in treatment group and control group were(9.08±0.95)and(7.64±0.79)μg·L-1;ALP levels were(86.27±8.79)and(91.33±9.25)U·L-1;CTX-Ⅰ levels were(0.21±0.04)and(0.25±0.03)ng·mL-1;the above indexes were significantly different between control group and treatment group(all P＜0.05).The incidence of refracture in treatment group and control group were 10.00％and 2.50％,and the incidence of adverse drug reactions were 10.00％and 17.50％,without statistically significant difference between the two groups(all P＞0.05).Conclusion Menatetrenone combined with PKP can significantly increase bone mineral density of patients with OVCF,improve bone metabolism indicators and reduce lumbar dysfunction and pain,without increasing the risks of refracture and adverse drug reactions.
